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INTRODUCTION
Traditional standard breast cancer surgery is composed
of total mastectomy and axillary lymph node dissection
(ALND). Three decades ago, total mastectomy was
challenged by Veronesi, with the proposal that partial
mastectomy with radiotherapy to the remaining breast
tissue produces a similar outcome to total mastectomy in
early breast cancer.1 ALND is still a standard surgical
procedure in the treatment of breast cancer, with or
without axillary lymph node (ALN) metastasis.
Nonetheless, complications from ALND are still
problematic. Other methods have failed to surpass ALND.
2 Cabanas proposed the “sentinel lymph node” (SLN)
concept in 1977 and applied this to breast cancer patients,
thus allowing patients with negative axillary nodes to be
spared from ALND.3
The basis of the SLN concept is that the cancer
metastasizes first to one node before spreading to the
other nodes. This first node is called the SLN; if the SLN is
free of cancer, one can assume that the rest of the lymph
nodes are also cancer-free. Therefore, lymph node
dissection and its related complications can be avoided.
The impression from numerous ongoing clinical trials4–7
is that ALND is not required for breast cancer patients with
a negative SLN.
The incidence of breast cancer among Chinese women
is increasing,8 as is the number of patients with clinically
impalpable axillary lymph nodes. Is this new trend suitable
for Chinese breast cancer patients? A summary of SLN
findings on Chinese breast cancer patients and those of
European and American patients is presented in this issue.
SLN MAPPING
The SLN is identified during surgery with the use of a
tracer injected into the tumour area and allowing the dye
to flow via the lymphatics to the SLN. Currently, either
blue dye or isotope-labeled human albumin or sulfur
colloids are used as tracers. The advantage of blue dye is
that it is easy to use and quick to perform. However, there
is the risk of allergy, transient hypotension, staining of the
breast and urine, and more difficult and extensive
dissection.9
Isotope labeling methods (e.g., 99mtechnetium [99mTc])
do not have the disadvantages of blue dye, although
surgery should be done at least 2 hours after 99mTc
injection and a gamma probe is necessary to localize the
SLN during surgery.
The colloid in general use is small (usually < 200 nm).
Colloids that are too large may cause an “axillary
contamination” effect,6 but those that are too small may
fail to identify the SLN.10 Failure to locate the SLN on
preoperative lymphoscintigraphy is a serious problem
and this failure rate is reported to be between 5% and
10%.4–7 When we began using this technique at our
centre, our failure rate was 6.9%. An alternative method
was developed in our institute using a larger colloid on
patients whose SLNs had failed to show with colloid of the
usual size. So far, all but one SLN has failed to show.11
Timing of isotope injection does not interfere with SLN
harvesting, but injection carried out on the day prior to
surgery means that there is less radioactivity during surgery,
more time to change to a larger size of colloid and more
time to perform surgery.
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the axilla. Rozenberg et al stated that false negativity
is inevitable in the SLN work-up.15 As the vast majority
of breast cancer patients with a negative SLN also
have negative ALNs, ALND can be avoided in breast
cancer patients where a negative SLN is confirmed. This
conclusion is applicable to Chinese breast cancer patients
also.
CONCLUSION
The results of SLN mapping and resection in breast
cancer among Chinese women is comparable to the
results from European and American patients. Notably,
the negative predictive rate is similar. SLN mapping and
resection is applicable to Chinese breast cancer patients.
Those with impalpable ALNs should undergo an SLN
work-up. If the SLN is negative for cancer metastasis,
ALN dissection can be avoided.
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SLN RESECTION
Under the guidance of a gamma probe, hot node(s)
can be found and resected through a small incision in the
axilla. Localization is done using an audio-guided signal
and the direction of the probe should be away from the
tumour to avoid the “shining” effect. Completion of SLN
resection is indicated by the difference in radioactivity
between the post-SLN-resected axilla and background
radioactivity. In our unpublished data, this difference
value is either equal to, or less than, zero. The nodes with
tracer uptake are totally removed under this principle.
Each hot node may contain one or more lymph nodes.
Any node with a radioactivity greater than that of the
background is taken to be the SLN. According to the
original SLN concept, the number of SLNs should be one
or two. Nonetheless, reported data, including ours, showed
that the number of SLNs can be higher.12
PATHOLOGY OF SLN
The routine pathological examination of cancer
metastasis in SLN is done using the H & E staining
technique. Nonetheless, if only a few cancer cells are
present in a corner of the SLN or just under the capsule of
the SLN, this micrometastasis may not be identified by H
& E staining. Currently, this problem can be solved by
cytokeratine immunohistochemistry (IHC) staining. By
using this technique, a 10% to 14 % conversion rate of
pathologically negative diagnoses has been reported.13
The Ludwig Breast Cancer Study Group found that patients
with micrometastases had a significantly worse survival
rate than those without micrometastases.14 For this reason,
cytokeratine IHC staining is recommended for patients
negative for a SLN. It is generally agreed that the number
of SLNs harvested has no relation to the actual number of
metastases to the SLN.4–7 Resection of all SLNs is necessary
as a positive SLN may not be found at resection, even in
patients with multiple SLNs.
PATHOLOGICAL CONCORDANCE OF SLN AND ALN
The key concern of the SLN work-up in breast cancer
is whether the SLN is really representative of cancer in the
axilla. From all reported series including our own, the
negative predictive value has been recorded at 95%
to 98%.4–7 The false negative results are similar to
historical reports of breast cancer skip metastasis at
Asian Journal of Surgery 197
SENTINEL LYMPH NODE MAPPING IN BREAST CANCER
Eur J Surg Oncol 1999;26:103–4.
13. McIntosh SA, Going JJ, Soukop M, et al. Therapeutic
implications of the sentinel lymph node in breast cancer.
Lancet 1999;354:570.
14. International (Ludwig) Breast Cancer Study Group. Prognostic
importance of occult axillary lymph node micrometastases
from breast cancers. Lancet 1990;335:1565–8.
15. Rozenberg S, Liebens F, Ham H. The sentinel lymph node in
breast cancer: acceptable false negative rate. Lancet 1999;
353:1937–8.
